245 related articles for article (PubMed ID: 17683622)
1. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.
Friedenson B
BMC Cancer; 2007 Aug; 7():152. PubMed ID: 17683622
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
Friedenson B
MedGenMed; 2005 Jun; 7(2):60. PubMed ID: 16369438
[TBL] [Abstract][Full Text] [Related]
3. The biological effects and clinical implications of BRCA mutations: where do we go from here?
Stoppa-Lyonnet D
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
[TBL] [Abstract][Full Text] [Related]
4. Clinical
Pettitt SJ; Frankum JR; Punta M; Lise S; Alexander J; Chen Y; Yap TA; Haider S; Tutt ANJ; Lord CJ
Cancer Discov; 2020 Oct; 10(10):1475-1488. PubMed ID: 32699032
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of BRCA1 alternative splicing.
Orban TI; Olah E
Mol Pathol; 2003 Aug; 56(4):191-7. PubMed ID: 12890739
[TBL] [Abstract][Full Text] [Related]
6. Double-strand breaks and translocations in cancer.
Elliott B; Jasin M
Cell Mol Life Sci; 2002 Feb; 59(2):373-85. PubMed ID: 11915950
[TBL] [Abstract][Full Text] [Related]
7. Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.
Setton J; Hadi K; Choo ZN; Kuchin KS; Tian H; Da Cruz Paula A; Rosiene J; Selenica P; Behr J; Yao X; Deshpande A; Sigouros M; Manohar J; Nauseef JT; Mosquera JM; Elemento O; Weigelt B; Riaz N; Reis-Filho JS; Powell SN; Imieliński M
Nature; 2023 Sep; 621(7977):129-137. PubMed ID: 37587346
[TBL] [Abstract][Full Text] [Related]
8. Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.
Lee IH; Lee SJ; Kim J; Lee YH; Chong GO; Kim JM; Lee J; Lee NY; Park SY; Hong DG; Chae YS
Cancer Chemother Pharmacol; 2024 Apr; ():. PubMed ID: 38652271
[TBL] [Abstract][Full Text] [Related]
9.
Shah PD; Nathanson KL
Haematologica; 2024 Jan; 109(1):21-22. PubMed ID: 37470159
[No Abstract] [Full Text] [Related]
10. Discovery of cancer common and specific driver gene sets.
Zhang J; Zhang S
Nucleic Acids Res; 2017 Jun; 45(10):e86. PubMed ID: 28168295
[TBL] [Abstract][Full Text] [Related]
11. Chromothripsis in hematologic malignancies.
Lagunas-Rangel FA
Exp Hematol; 2024 Apr; 132():104172. PubMed ID: 38309572
[TBL] [Abstract][Full Text] [Related]
12. Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local.
Patel-Donnelly D; Gandhi M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):311-317. PubMed ID: 38066909
[TBL] [Abstract][Full Text] [Related]
13. Risks and chances of aberrant DNA repair in cancer.
Schubert M; Greil R; Geisberger R
Oncoscience; 2018 Sep; 5(9-10):256-257. PubMed ID: 30460325
[No Abstract] [Full Text] [Related]
14. Involvement of Brca2 in DNA repair.
Patel KJ; Yu VP; Lee H; Corcoran A; Thistlethwaite FC; Evans MJ; Colledge WH; Friedman LS; Ponder BA; Venkitaraman AR
Mol Cell; 1998 Feb; 1(3):347-57. PubMed ID: 9660919
[TBL] [Abstract][Full Text] [Related]
15. The BRCA mutation spectrum among breast and ovarian cancers in India: highlighting the need to screen BRCA1 185delAG among South Indians.
John AO; Singh A; Yadav P; Joel A; Thumaty DB; Fibi Ninan K; Georgy JT; Cherian AJ; Thomas S; Thomas A; Thomas V; Peedicayil A; Varghese D; Parthiban R; Ravichandran L; Johnson J; Thomas N; Yadav B; Patricia S; Selvamani B; Abraham D; Paul MJ; Chacko RT; Chapla A
Eur J Hum Genet; 2024 Mar; ():. PubMed ID: 38538877
[TBL] [Abstract][Full Text] [Related]
16. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
[TBL] [Abstract][Full Text] [Related]
17. Assessing Psychological Morbidity in Cancer-Unaffected
Isselhard A; Lautz Z; Rhiem K; Stock S
Curr Oncol; 2023 Mar; 30(4):3590-3608. PubMed ID: 37185387
[TBL] [Abstract][Full Text] [Related]
18. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
Stecklein SR; Kimler BF; Yoder R; Schwensen K; Staley JM; Khan QJ; O'Dea AP; Nye LE; Elia M; Heldstab J; Home T; Hyter S; Isakova K; Pathak HB; Godwin AK; Sharma P
NPJ Breast Cancer; 2023 Mar; 9(1):10. PubMed ID: 36878909
[TBL] [Abstract][Full Text] [Related]
19. Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-Unaffected
Isselhard A; Lautz Z; Töpper M; Rhiem K; Schmutzler R; Vitinius F; Fischer H; Berger-Höger B; Steckelberg A; Beifus K; Köberlein-Neu J; Stock S
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767056
[TBL] [Abstract][Full Text] [Related]
20. Natural Compounds or Their Derivatives against Breast Cancer: A Computational Study.
Hossain R; Ray P; Sarkar C; Islam MS; Khan RA; Khalipha ABR; Islam MT; Cho WC; Martorell M; Sharifi-Rad J; Butnariu M; Umbetova A; Calina D
Biomed Res Int; 2022; 2022():5886269. PubMed ID: 35837379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
